Summit Therapeutics PLC (SMMT) Price Target Increased to $30.00 by Analysts at Needham & Company LLC
Summit Therapeutics PLC (NASDAQ:SMMT) had its price objective lifted by Needham & Company LLC from $22.00 to $30.00 in a report released on Tuesday morning. They currently have a buy rating on the stock.
Other equities analysts also recently issued reports about the company. HC Wainwright started coverage on Summit Therapeutics PLC in a research report on Friday, September 16th. They issued a buy rating and a $26.00 target price on the stock. Zacks Investment Research raised Summit Therapeutics PLC from a hold rating to a buy rating and set a $7.00 target price on the stock in a research report on Wednesday, September 14th. Canaccord Genuity reissued a buy rating and issued a $14.00 target price on shares of Summit Therapeutics PLC in a research report on Friday, September 9th. Janney Montgomery Scott started coverage on Summit Therapeutics PLC in a research report on Tuesday, June 21st. They issued a buy rating on the stock. Finally, Oppenheimer Holdings Inc. reissued a buy rating on shares of Summit Therapeutics PLC in a research report on Thursday, June 16th. Six research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average target price of $21.00.
Shares of Summit Therapeutics PLC (NASDAQ:SMMT) traded up 1.25% during trading on Tuesday, hitting $14.53. The stock had a trading volume of 271,205 shares. Summit Therapeutics PLC has a 12-month low of $4.26 and a 12-month high of $19.75. The firm has a 50 day moving average price of $7.48 and a 200 day moving average price of $7.68. The firm’s market cap is $178.63 million.
A hedge fund recently bought a new stake in Summit Therapeutics PLC stock. Granite Point Capital Management L.P. purchased a new stake in Summit Therapeutics PLC (NASDAQ:SMMT) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 112,676 shares of the company’s stock, valued at approximately $891,000. Granite Point Capital Management L.P. owned approximately 0.92% of Summit Therapeutics PLC as of its most recent SEC filing. 23.43% of the stock is currently owned by hedge funds and other institutional investors.
About Summit Therapeutics PLC
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.